Pronova Biocare signs new European deal

Published: 19-Jan-2002


Norwegian company Pronova Biocare has signed two separate licence and supply agreements for the pharmaceutical product Omacor. The agreements, with Solvay Pharmaceuticals and Grupo Ferrer Internacional, cover Germany, the UK and Spain and represent a substantial increase in the potential sales of Omacor, a 92% concentrate of Omega-3 ethyl esters. Under the terms of the deal, Pronova Biocare is responsible for the development and manufacturing of Omacor, while Solvay and Ferrer will ensure sales, marketing and distribution.

The active ingredient is manufactured at Pronova Biocare's plant in Sandefjord, Norway. It is produced from unrefined marine oils and the finished product contains 84% of the Omega-3 ethyl esters EPA and DHA.

Omacor is approved in five EU countries — Germany, UK, France, Greece and Austria — for the secondary prevention of post-MI (heart attack) and for the treatment of hypertriglyceridemia.

You may also like